Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors-Reference-Cited by-同舟云学术

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors

Published:2011-03 Issue:3 Volume:54 Page:439-448
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Kurosaki Masayuki,Tanaka Yasuhito,Nishida Nao,Sakamoto Naoya,Enomoto Nobuyuki,Honda Masao,Sugiyama Masaya,Matsuura Kentaro,Sugauchi Fuminaka,Asahina Yasuhiro,Nakagawa Mina,Watanabe Mamoru,Sakamoto Minoru,Maekawa Shinya,Sakai Akito,Kaneko Shuichi,Ito Kiyoaki,Masaki Naohiko,Tokunaga Katsushi,Izumi Namiki,Mizokami Masashi

Publisher

Elsevier BV

Subject

Hepatology

Reference48 articles.

1. Global epidemiology and burden of hepatitis C;Ray Kim;Microbes Infect,2002

2. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection;Fried;N Engl J Med,2002

3. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial;Manns;Lancet,2001

4. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy;Akuta;Intervirology,2005

5. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C;Davis;Hepatology,2003

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single-molecule sequencing of the whole HCV genome revealed envelope deletions in decompensated cirrhosis associated with NS2 and NS5A mutations;Journal of Gastroenterology;2024-09-03

2. Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies;Scientific Reports;2023-03-01

3. The impact of single‑nucleotide polymorphisms on liver stiffness and controlled attenuation parameter in patients treated with direct‑acting antiviral drugs for hepatitis C infection;Biomedical Reports;2021-12-07

4. IL28B遺伝子多型の発見から臨床応用②臨床応用;Kanzo;2021-04-01

5. PNPLA3 and IL 28B signature for predicting susceptibility to chronic hepatitis C infection and fibrosis progression;Archives of Physiology and Biochemistry;2019-12-03